Crescent Biopharma, Inc. CBIO
13.99
(0.25)
(1.76%)
as of 25 Sep
- Market cap
- $528.9M
- P/E
- 0.0×
Follow CBIO
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | — | — |
+8 more quarters Free account |
P/S ratio |
— | 458.39 | — | — | |
P/FCF ratio |
— | 0.00 | — | — | |
P/Operating CF |
— | (62.48) | — | — | |
P/B ratio |
— | 3.10 | — | — | |
Price to Tangible BV |
— | 3.10 | — | — | |
EV/Sales |
— | 333.88 | — | — | |
EV/EBITDA |
— | 0.00 | — | — | |
EV/Operating CF |
— | (5.84) | — | — | |
EV/FCF |
— | (5.75) | — | — | |
Quick Ratio |
9.26 | 13.33 | 6.41 | 6.56 | |
Current Ratio |
9.66 | 13.78 | 6.56 | 6.63 | |
Net Debt/EBITDA |
6.52 | 7.67 | 2.08 | 5.15 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.01 | 0.00 | 0.00 | |
Operating CF/Net income |
0.78 | 0.38 | 0.29 | 0.71 | |
Capex/Depreciation |
26.62 | (2.30) | (3.57) | (20.93) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 1,723.10% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 756.98% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 395.86% | 0.00% | 0.00% | |
Graham Net Nets |
— | 0.32 | — | — | |
Graham Number |
— | 0.00 | — | — | |
Earnings Yield |
— | (59.39%) | — | — | |
Free Cash Flow Yield |
— | (12.66%) | — | — | |
Revenue per Share |
0.00 | 0.03 | 0.00 | 0.00 | |
Operating CF per Share |
(0.64) | (0.29) | (2.57) | (1.06) | |
Capex per Share |
0.06 | 0.00 | (0.02) | (0.04) | |
Free Cash Flow per Share |
(0.58) | (0.30) | (2.59) | (1.10) | |
Cash per Share |
5.62 | 6.22 | 20.47 | 8.06 | |
Shareholders Equity per Share |
5.35 | 6.05 | 19.49 | 7.05 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.35 | 6.05 | 19.49 | 7.05 | |
Free Cash Flow |
(17.71) | (9.08) | (26.93) | (18.12) | |
Working Capital |
160.47 | 181.37 | 200.58 | 114.26 | |
Capital Expenditures |
1.76 | (0.15) | (0.19) | (0.59) | |
Net Current Asset Value |
159.50 | 180.28 | 199.37 | 112.94 | |
EV/EBIT |
— | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.14 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | (2,240.90%) | 0.00% | 0.00% | |
Price to Operating Income |
— | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
— | — | 9.07 | — | |
Average Payables |
4.69 | 0.65 | 8.73 | 4.71 | |
Average Assets |
170.10 | 102.56 | 137.96 | 76.98 | |
Average Common Equity |
147.25 | 91.61 | 91.77 | 62.01 |
Columns are period end dates